Regular Use of VKA Prior to COVID-19 Associated with Lower 7-Day Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Cohort Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population
2.2. Regular Use of Vitamin K Antagonists
2.3. Outcome: 7-Day Mortality in COVID-19 Patients
2.4. Covariables
2.5. Statistical Analysis
2.6. Ethics
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020, 395, 1054–1062. [Google Scholar] [CrossRef]
- Cui, S.; Chen, S.; Li, X.; Liu, S.; Wang, F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneu-monia. J. Thromb. Haemost. 2020, 18, 1421–1424. [Google Scholar] [CrossRef]
- Tang, N.; Li, D.; Wang, X.; Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020, 18, 844–847. [Google Scholar] [CrossRef] [Green Version]
- Dofferhoff, A.S.M.; Piscaer, I.; Schurgers, L.J.; Visser, M.P.J.; Ouweland, J.M.W.V.D.; A De Jong, P.; Gosens, R.; Hackeng, T.M.; Van Daal, H.; Lux, P.; et al. Reduced vitamin K status as a potentially modifiable risk factor of severe COVID-19. Clin. Infect. Dis. 2020. [Google Scholar] [CrossRef]
- Luo, W.-R.; Yu, H.; Gou, J.-Z.; Li, X.-X.; Sun, Y.; Li, J.-X.; He, J.-X.; Liu, L. Histopatological Findings in the Explant Lungs of a Patient With COVID-19 Treated With Bilateral Orthotopic Lung Transplant. Transplantation 2020, 104, e329–e331. [Google Scholar] [CrossRef]
- Fraser, J.D.; A Price, P. Lung, heart, and kidney express high levels of mRNA for the vitamin K-dependent matrix Gla protein. Implications for the possible functions of matrix Gla protein and for the tissue distribution of the gamma-carboxylase. J. Biol. Chem. 1988, 263, 11033–11036. [Google Scholar]
- Ansell, J.; Hirsh, J.; Hylek, E.; Jacobson, A. Crowther M, Palareti G. American College of Chest Physicians: Pharmacology and Management of the Vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133, 160S–198S. [Google Scholar] [CrossRef]
- French National Security Agency of Medicines and Health Products (ANSM). Anticoagulants in France in 2012: Inventory and Monitoring. Available online: http://ansm.sante.fr/var/ansm_site/storage/original/application/901e9c291a545dff52c0b41365c0d6e2.pdf (accessed on 26 November 2020).
- Gąsecka, A.; Borovac, J.A.; Guerreiro, R.A.; Giustozzi, M.; Parker, W.A.; Caldeira, D.; Chiva-Blanch, G. Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment. Cardiovasc. Drugs Ther. 2020, 2020, 1–15. [Google Scholar] [CrossRef]
- Vetel, J.M.; Leroux, R.; Ducoudray, J.M. AGGIR. Practical use. Geriatric Autonomy Group Resources Needs. Soins Gérontol. 1998, 13, 23–27. [Google Scholar]
- Developed with the special contribution of the European Heart Rhythm Association (EHRA); Camm, A.J.; Kirchhof, P.; Lip, G.Y.; Schotten, U.; Savelieva, I.; Ernst, S.; Van Gelder, I.C.; Al-Attar, N.; Hindricks, G.; et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 2010, 31, 2369–2429. [Google Scholar] [CrossRef]
- Li, F.; Morgan, K.L.; Zaslavsky, A.M. Balancing Covariates via Propensity Score Weighting. J. Am. Stat. Assoc. 2018, 113, 390–400. [Google Scholar] [CrossRef] [Green Version]
- Flaczyk, A.; Rosovsky, R.; Reed, C.T.; Bankhead-Kendall, B.K.; Bittner, E.A.; Chang, M.G. Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: Implications for clinical practice and future investigations. Crit. Care 2020, 24, 1–13. [Google Scholar] [CrossRef] [PubMed]
- Tremblay, D.; Van Gerwen, M.; Alsen, M.; Thibaud, S.; Kessler, A.; Venugopal, S.; Makki, I.; Qin, Q.; Dharmapuri, S.; Jun, T.; et al. Impact of anticoagulation prior to COVID-19 infection: A propensity score–matched cohort study. Blood 2020, 136, 144–147. [Google Scholar] [CrossRef] [PubMed]
- Tang, N.; Bai, H.; Chen, X.; Gong, J.; Li, D.; Sun, Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020, 18, 1094–1099. [Google Scholar] [CrossRef]
- Nadkarni, G.N.; Lala, A.; Bagiella, E.; Chang, H.L.; Moreno, P.R.; Pujadas, E.; Arvind, V.; Bose, S.; Charney, A.W.; Chen, M.D.; et al. Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. J. Am. Coll. Cardiol. 2020, 76, 1815–1826. [Google Scholar] [CrossRef]
- Booth, S.L.; Martini, L.; Peterson, J.W.; Saltzman, E.; Dallal, G.E.; Wood, R.J. Dietary Phylloquinone Depletion and Repletion in Older Women. J. Nutr. 2003, 133, 2565–2569. [Google Scholar] [CrossRef] [Green Version]
- Nigwekar, S.U.; Thadhani, R.; Brandenburg, V.M. Calciphylaxis. N. Engl. J. Med. 2018, 378, 1704–1714. [Google Scholar] [CrossRef]
- Chatrou, M.L.; Winckers, K.; Hackeng, T.M.; Reutelingsperger, C.P.; Schurgers, L.J. Vascular calcification: The price to pay for anti-coagulation therapy with vitamin K-antagonists. Blood Rev. 2012, 26, 155–166. [Google Scholar] [CrossRef]
- Price, P.A.; Buckley, J.R.; Williamson, M.K. The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vita-min D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J. Nutr. 2001, 131, 2910–2915. [Google Scholar] [CrossRef] [Green Version]
- Rucker, R.B. Calcium Binding to Elastin. Adv. Exp. Med. Biol. 1974, 48, 185–209. [Google Scholar] [CrossRef]
- Schurgers, L.J.; Spronk, H.M.; Soute, B.A.; Schiffers, P.M.; DeMey, J.G.; Vermeer, C. Regression of warfarin-induced medial elastocal-cinosis by high intake of vitamin K in rats. Blood 2007, 109, 2823–2831. [Google Scholar] [CrossRef]
- Hardie, W.D.; Korfhagen, T.R.; Sartor, M.A.; Prestridge, A.; Medvedovic, M.; Le Cras, T.D.; Ikegami, M.; Wesselkamper, S.C.; Davidson, C.; Dietsch, M.; et al. Genomic profile of matrix and vasculature remodeling in TGF-α in-duced pulmonary fibrosis. Am. J. Respir. Cell. Mol. Biol. 2007, 37, 309–321. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Booth, A.J.; Hadley, R.; Cornett, A.M.; Dreffs, A.A.; Matthes, S.A.; Tsui, J.L.; Weiss, K.; Horowitz, J.C.; Fiore, V.F.; Barker, T.H.; et al. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am. J. Respir. Crit. Care Med. 2012, 186, 866–876. [Google Scholar] [CrossRef] [Green Version]
- Basalyga, D.M.; Simionescu, D.T.; Xiong, W.; Baxter, B.T.; Starcher, B.C.; Vyavahare, N.R. Elastin degradation and calcification in an abdominal aorta injury model: Role of matrix metalloproteinases. Circulation 2004, 110, 3480–3487. [Google Scholar] [CrossRef]
- Westenfeld, R.; Krueger, T.; Schlieper, G.; Cranenburg, E.C.; Magdeleyns, E.J.; Heidenreich, S. Effect of vitamin K2 supplemen-tation on functional vitamin K deficiency in hemodialysis patients: A randomized trial. Am. J. Kidney Dis. 2012, 59, 186–195. [Google Scholar] [CrossRef] [PubMed]
- Urawa, M.; Kobayashi, T.; D’Alessandro-Gabazza, C.N.; Fujimoto, H.; Toda, M.; Roeen, Z.; A Hinneh, J.; Yasuma, T.; Takei, Y.; Taguchi, O.; et al. Protein S is protective in pulmonary fibrosis. J. Thromb. Haemost. 2016, 14, 1588–1599. [Google Scholar] [CrossRef] [Green Version]
- Lin, C.; Von Der Thüsen, J.; Isermann, B.; Weiler, H.; Van Der Poll, T.; Borensztajn, K.; Spek, C.A. High endogenous activated protein C levels attenuates bleomycin-induced pulmonary fibrosis. J. Cell. Mol. Med. 2016, 20, 2029–2035. [Google Scholar] [CrossRef] [Green Version]
- Suleiman, L.; Negrier, C.; Boukerche, H. Protein S: A multifunctional anticoagulant vitamin K-dependent protein at the cross-roads of coagulation, inflammation, angiogenesis, and cancer. Crit. Rev. Oncol. Hematol. 2013, 88, 637–654. [Google Scholar] [CrossRef]
- Anastasi, E.; Ialongo, C.; Labriola, R.; Ferraguti, G.; Lucarelli, M.; Angeloni, A. Vitamin K deficiency and covid-19. Scand. J. Clin. Lab. Investig. 2020, 80, 525–527. [Google Scholar] [CrossRef] [PubMed]
Total Cohort (n = 82) | 7-Day Mortality | p-Value * | ||
---|---|---|---|---|
No (n = 73) | Yes (n = 9) | |||
Demographical data | ||||
Age (years), med (IQR) | 88 (85–92) | 88 (85–92) | 89 (87–92) | 0.655 |
Female sex | 39 (47.6) | 35 (48.0) | 4 (44.4) | 1.000 |
GIR score (/6), med (IQR) | 4 (2–4) | 4 (2–4) | 3 (2–4) | 0.387 |
History and treatment data | ||||
History of cancer | 29 (35.4) | 23 (31.5) | 6 (66.7) | 0.061 |
Severe undernutrition † | 25 (30.9) | 20 (27.8) | 5 (55.6) | 0.126 |
History of diabetes mellitus | 19 (23.2) | 18 (24.7) | 1 (11.1) | 0.677 |
History of hypertension | 52 (63.4) | 46 (63.0) | 6 (66.7) | 1.000 |
History of cardiomyopathy | 44 (53.7) | 39 (53.4) | 5 (55.6) | 1.000 |
History of myocardial infarction | 16 (19.5) | 13 (17.8) | 3 (33.3) | 0.368 |
History of congestive heart failure | 26 (31.7) | 23 (31.5) | 3 (33.3) | 1.000 |
History of stroke and/or transient ischemic attack | 16 (19.5) | 14 (19.2) | 2 (22.2) | 1.000 |
CHA2DS2-VASc score, med (IQR) | 4 (3–5) | 4 (3–5) | 5 (3–5) | 0.957 |
HAS-BLED score, med (IQR) | 2 (2–3) | 2 (2–3) | 3 (2–4) | 0.111 |
Regular use of vitamin K antagonist prior to COVID-19 | 9 (11.0) | 6 (8.2) | 3 (33.3) | 0.056 |
Hospitalization data | ||||
Non-sinus heart rhythm on admission | 30 (36.6) | 28 (38.4) | 2 (22.2) | 0.475 |
Use of antibiotics ‡ | 59 (72.0) | 52 (71.2) | 7 (77.8) | 1.000 |
Use of pharmacological treatments of respiratory disorders || | 9 (11.0) | 6 (8.2) | 3 (33.3) | 0.056 |
Estimated glomerular filtration rate (mL/min) §, med (IQR) | 71.6 (52.8–93.1) | 71.8 (53.7–92.7) | 42.6 (34.2–101.4) | 0.244 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ménager, P.; Brière, O.; Gautier, J.; Riou, J.; Sacco, G.; Brangier, A.; Annweiler, C.; on behalf of the GERIA-COVID study group. Regular Use of VKA Prior to COVID-19 Associated with Lower 7-Day Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Cohort Study. Nutrients 2021, 13, 39. https://doi.org/10.3390/nu13010039
Ménager P, Brière O, Gautier J, Riou J, Sacco G, Brangier A, Annweiler C, on behalf of the GERIA-COVID study group. Regular Use of VKA Prior to COVID-19 Associated with Lower 7-Day Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Cohort Study. Nutrients. 2021; 13(1):39. https://doi.org/10.3390/nu13010039
Chicago/Turabian StyleMénager, Pierre, Olivier Brière, Jennifer Gautier, Jérémie Riou, Guillaume Sacco, Antoine Brangier, Cédric Annweiler, and on behalf of the GERIA-COVID study group. 2021. "Regular Use of VKA Prior to COVID-19 Associated with Lower 7-Day Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Cohort Study" Nutrients 13, no. 1: 39. https://doi.org/10.3390/nu13010039
APA StyleMénager, P., Brière, O., Gautier, J., Riou, J., Sacco, G., Brangier, A., Annweiler, C., & on behalf of the GERIA-COVID study group. (2021). Regular Use of VKA Prior to COVID-19 Associated with Lower 7-Day Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Cohort Study. Nutrients, 13(1), 39. https://doi.org/10.3390/nu13010039